Health sciences

Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Mental health, Health, Pharmaceutical, Managed care, GABAA receptor positive allosteric modulators, Psychoactive drugs, Anticonvulsants, Chemical compounds, Health sciences, Ketones, Pregnanes, Sterols, CDKL5 deficiency disorder, Ganaxolone, CDKL5, Allosteric modulator

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.

Key Points: 
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • Marinus completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder last year and is conducting a Phase 2 trial in tuberous sclerosis complex and a Phase 3 trial in refractory status epilepticus.

Worldwide Clinical Trials’ Aman Khera Recognized Among Pharmavoice 100 Most Inspiring People

Retrieved on: 
Tuesday, August 3, 2021
Professional services, Health, Other Professional Services, Clinical trials, Research, Science, Pharmaceutical, Health sciences, Clinical research, Health, Pharmaceutical industry, Life sciences, Biotechnology, Contract research organization, Pharmaceuticals policy, Clinical trial

Worldwide Clinical Trials , Inc. (Worldwide), the industrys leading global, midsized, full-service contract research organization (CRO), today announced that its Vice President, Global Head of Regulatory Strategy Aman Khera has been recognized as one of the 100 Most Inspiring People in the Life Sciences Industry by PharmaVOICE.

Key Points: 
  • Worldwide Clinical Trials , Inc. (Worldwide), the industrys leading global, midsized, full-service contract research organization (CRO), today announced that its Vice President, Global Head of Regulatory Strategy Aman Khera has been recognized as one of the 100 Most Inspiring People in the Life Sciences Industry by PharmaVOICE.
  • In all that she does, Aman champions the strategic role of regulatory professionals and advocates for diversity, inclusion and belonging in clinical research.
  • Amans tireless efforts and pursuit of regulatory excellence have contributed to Worldwides continued growth and success, said Henry Riordan, PhD, Chief Development Officer, Worldwide Clinical Trials.
  • Congratulations to Aman Khera and the other 2021 PharmaVOICE 100 honorees, said Peter Benton, President and co-CEO of Worldwide.

OnKure Expands Executive Team with the Addition of Chief Scientific Officer and Chief Development Officer

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Pharmaceutical industry, Health sciences, Life sciences, Drug discovery, Pharmacology, Preclinical development, Medication, Arcturus Therapeutics

He joined Arvinas as the Chief Scientific Officer, helping the new company focus on a novel technology, validating and further advancing this technology, and building a growing preclinical pipeline, enabling Arvinas to go public.

Key Points: 
  • He joined Arvinas as the Chief Scientific Officer, helping the new company focus on a novel technology, validating and further advancing this technology, and building a growing preclinical pipeline, enabling Arvinas to go public.
  • I am thrilled to be joining forces with such an experienced team of drug discovery and development scientists, said Dr. Winkler.
  • Dr. Walker has a proven track record in cancer drug discovery and development, including contributions to the discovery and development of three FDA-approved medicines.
  • OnKure has reconstituted a management team that has previously worked together to create breakthrough precision cancer medicines, said Tony Piscopio, Ph.D., Co-Founder, President and Chief Executive Officer of OnKure.

Industry Veteran John Yee, MD, MPH Joins ReForm Biologics Board of Directors

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Health, Science, Pharmaceutical, Research, Life sciences, Health sciences, Biotechnology, Pharmaceutical industry, Biopharmaceutical, Pharmacy, Intravenous therapy

ReForm Biologics , Inc., a company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that John Yee, MD, MPH has joined the companys Board of Directors.

Key Points: 
  • ReForm Biologics , Inc., a company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that John Yee, MD, MPH has joined the companys Board of Directors.
  • On behalf of all of us at ReForm, I welcome John to the Board and we look forward to his contributions.
  • Prior to joining industry, John held leadership roles at Boston Childrens Hospital and was a faculty member at Harvard Medical School.
  • Currently, most biologics are administered as intravenous infusions which can be time consuming as well as uncomfortable for patients.

Covetrus Announces $120K in Scholarships to Support Diversity in Veterinary Sector

Retrieved on: 
Tuesday, August 3, 2021
Software, Philanthropy, Pharmaceutical, Data management, Consumer, Technology, University, Fund Raising, Education, Veterinary, Other Philanthropy, Health, Pets, Health sciences, Veterinary medicine, Health, Animal health, Animal husbandry, Medicated feed, Pharmacy, Veterinary pharmacy, Veterinarian

The Covetrus Diversity Scholarship in Veterinary Medicine and the Covetrus Diversity Scholarship in Veterinary Pharmacy are new initiatives for the company developed to enable more accessibility and diversity within the veterinary industry.

Key Points: 
  • The Covetrus Diversity Scholarship in Veterinary Medicine and the Covetrus Diversity Scholarship in Veterinary Pharmacy are new initiatives for the company developed to enable more accessibility and diversity within the veterinary industry.
  • The veterinary industry should reflect the pet parents we serve in the communities we service and that means making space for diverse candidates.
  • Covetrus supports the University of New Englands School of Pharmacy (UNE) by offering advanced pharmacy practice experience (APPE) to pharmacy doctoral candidates enrolled there.
  • Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes.

NorthStar Medical Radioisotopes and GE Healthcare Sign Exclusive U.S. Manufacturing and Distribution Agreement

Retrieved on: 
Tuesday, August 3, 2021
Medical Supplies, Health, Hospitals, General Health, Pharmaceutical, Biotechnology, Medicine, Health sciences, Radiopharmaceuticals, Physical sciences, Medical physics, Medicinal radiochemistry, Medicinal chemistry, Nuclear medicine, GE Healthcare, General Electric, Medical imaging, Radiopharmacology

NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, and GE Healthcare today announced the signing of an exclusive agreement for the manufacturing and distribution of iodine-123 (I-123) capsules in the United States.

Key Points: 
  • NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, and GE Healthcare today announced the signing of an exclusive agreement for the manufacturing and distribution of iodine-123 (I-123) capsules in the United States.
  • This exclusive sales and manufacturing agreement marks NorthStars strong and growing relationship with GE Healthcare, and we look forward to working with the company in meeting the needs of radiopharmacy customers and the patients we all serve, said Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes.
  • GE Healthcare Pharmaceutical Diagnostics imaging agents support three patient procedures every second worldwide across MRI, X-ray/CT, ultrasound and nuclear medicine imaging.
  • GE Healthcare is the $18 billion healthcare business of GE (NYSE: GE).

Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

Retrieved on: 
Tuesday, August 3, 2021
Oncology, Health, Infectious diseases, Research, Science, Pharmaceutical, Biotechnology, Life sciences, Biotechnology, Health sciences, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Targeted therapy

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that the Company will participate in the 2021 Wedbush PacGrow Healthcare Conference from August 10-11, 2021.

Key Points: 
  • Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that the Company will participate in the 2021 Wedbush PacGrow Healthcare Conference from August 10-11, 2021.
  • Laura Shawver, Ph.D., Silverbacks Chief Executive Officer, will participate in the Heavenly (anti)Bodies panel on Tuesday, August 10, 2021 at 1:10 p.m.
  • Members of the Silverback management team will also host investor meetings during the conference.
  • Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.

Nordic Nanovector Provides Update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma

Retrieved on: 
Wednesday, August 4, 2021
Drugs, Orphan drugs, Health care, Health sciences, Rituximab, CD20, Breakthrough therapy

OSLO, Norway, Aug. 4, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) in 3rd-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL).

Key Points: 
  • OSLO, Norway, Aug. 4, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) in 3rd-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL).
  • The Company will host a live webcast and Q&A on Thursday, 5 August 2021, at 08.30 CEST.
  • A link to the webcast will beavailable in the afternoon on Wednesday, 4 August on www.nordicnanovector.com .
  • In addition, the Company confirms it will invest no further funds in its Archer-1 Phase 1b trial investigating Betalutin in combination with rituximab in 2nd-line FL.

Nordic Nanovector Provides Update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma

Retrieved on: 
Wednesday, August 4, 2021
Drugs, Orphan drugs, Health care, Health sciences, Rituximab, CD20, Breakthrough therapy

OSLO, Norway, Aug. 3, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) in 3rd-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL).

Key Points: 
  • OSLO, Norway, Aug. 3, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) in 3rd-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL).
  • The Company will host a live webcast and Q&A on Thursday, 5 August 2021, at 08.30 CEST.
  • A link to the webcast will beavailable in the afternoon on Wednesday, 4 August on www.nordicnanovector.com .
  • In addition, the Company confirms it will invest no further funds in its Archer-1 Phase 1b trial investigating Betalutin in combination with rituximab in 2nd-line FL.

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, August 3, 2021
Medical specialties, Adjuvants, Health sciences, Health, Clinical trials, Economy of New York City, NASDAQ, Immunologic adjuvant, Vaccine

The stock options were granted on August 2, 2021 at an exercise price of $9.45 per share, which is equal to the closing price of Dynavax common stock on the date of grant.

Key Points: 
  • The stock options were granted on August 2, 2021 at an exercise price of $9.45 per share, which is equal to the closing price of Dynavax common stock on the date of grant.
  • The options were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of a stock option agreement covering the grant and Dynavax' 2021 Inducement Award Plan, which was adopted January 9, 2021 and provides for the granting of stock options to new employees.
  • Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines.
  • Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships.